Document Detail

Angiogenin and gestational trophoblastic tumors, a promising prognostic marker.
MedLine Citation:
PMID:  12705339     Owner:  NLM     Status:  MEDLINE    
The aim of this study was to evaluate the diagnostic and prognostic values of serum angiogenin concentration in cases with gestational trophoblastic diseases (GTDs). Seventy-two patients with GTDs and 20 first trimester healthy pregnant women (controls) participated in this study. According to the WHO scoring system, GTDs were subgrouped into 24 hydatiform mole spontaneous regression (HMSR), 18 postmolar gestational trophoblastic tumors of high risk (PMHR), 16 low-risk choriocarcinoma, and 14 high-risk choriocarcinoma. Before treatment, a blood sample from each case was assayed for human chorionic gonadotrophin , subunit (hCGb) by radioimmunoassay and angiogenin by enzyme immunoassay. Follow-up hCGb and angiogenin assays were carried out for 1 year after treatment. Pretreatment of abnormal values of serum angiogenin (> 711 ng/ml, upper 95% confidence interval of controls) was encountered in 100% of PMHR cases compared to no single case of HMSR. Serum angiogenin levels in low- and high-risk cases with choriocarcinoma were significantly higher than in controls. Abnormal high values were encountered in 25% and 86% of cases, respectively. None of the low-risk cases exceeded 920 ng/ml, while 72% of high-risk cases exceeded this value. Serial angiogenin assays were correlated with disease progression and were positively correlated with serum hCGb (r = 0.75, p < 0.01). In conclusion, serum angiogenin may be a valuable marker of differential diagnosis of GTDs and its serial measurements are suggestive of remission and effective therapeutic intervention or disease progression.
Mohamed Shaarawy; Samira Y El-Mallah; Mamdouh Sheiba
Related Documents :
9519619 - Labor positions on worksite tobacco control policies: a review of arbitration cases.
1637899 - Reporting and selection bias in case-control studies of congenital malformations.
24627619 - Poor outcome of bilateral lower extremity morel-lavallee lesions: a case report.
7213149 - Abrupt neurological deterioration in children with kearns-sayre syndrome.
9663519 - Reliability of data on smoking habit and coffee drinking collected by personal intervie...
10194079 - Human herpesvirus 6 dna in cerebrospinal fluid specimens from allogeneic bone marrow tr...
18029389 - Are tribunals given appropriate and sufficient evidence for disability claims?
25480979 - Review of the genus sweltsa (plecoptera: chloroperlidae) in china.
23675569 - A rare der(y)t(y;1)(q12;q12) in a patient with post-polycythemic myelofibrosis: a case ...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study    
Journal Detail:
Title:  Clinical chemistry and laboratory medicine : CCLM / FESCC     Volume:  41     ISSN:  1434-6621     ISO Abbreviation:  Clin. Chem. Lab. Med.     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-04-22     Completed Date:  2003-12-03     Revised Date:  2011-07-19    
Medline Journal Info:
Nlm Unique ID:  9806306     Medline TA:  Clin Chem Lab Med     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  306-10     Citation Subset:  IM    
Endocrinology and Maternal Biochemistry Laboratories, Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Case-Control Studies
Choriocarcinoma / diagnosis
Chorionic Gonadotropin, beta Subunit, Human / blood
Diagnosis, Differential
Disease Progression
Gestational Trophoblastic Neoplasms / blood,  diagnosis*
Hydatidiform Mole / diagnosis
Pregnancy Trimester, First
Ribonuclease, Pancreatic / blood*
Risk Factors
Tumor Markers, Biological / blood*
Uterine Neoplasms / blood,  diagnosis*
Reg. No./Substance:
0/Chorionic Gonadotropin, beta Subunit, Human; 0/Tumor Markers, Biological; EC 3.1.27.-/angiogenin; EC, Pancreatic

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of partial proteolysis on the activation energy of beta-n-acetylhexosaminidase precursor and ...
Next Document:  Carbohydrate 19-9 antigen is not a marker of liver disease in patients with cystic fibrosis.